Genetic Association with Response to Intravitreal Ranibizumab in Patients with Neovascular AMD
Open accessThe DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.
Abstract
PURPOSE: Neovascular age-related macular degeneration (AMD) resulting in decreased central vision severely impairs affected individuals. Current standard treatment is an intravitreal anti-VEGF therapy (ranibizumab), but responses to treatment show large variability. Genetic factors that influence AMD and that affect the outcome of ranibizumab treatment were sought within a sample of Swiss patients. METHODS: Changes in visual acuity (VA) after initiation of anti-VEGF treatment were observed during 12 months, and percentiles of VA were calculated. Genotypes of polymorphisms in known AMD susceptibility loci (CFH, CFB, HTRA1, AMRS2, and VEGFA) as well as not yet reported AMD-associated genes (KDR, LRP5, and FZD4) were determined, and their frequencies were compared. RESULTS: Of the 309 eyes included in the study, 243 completed VA assessment. On average, 3.9 ±2.6 ranibizumab injections were administered. Based on the change in visual acuity, two responder groups were established: 63 eyes were assigned to the poor responders (≤25th percentile) and 63 eyes to the good responders (≥75th percentile). Individuals with genotype CC of p.Y402H in CFH had a decreased chance of positive treatment outcome compared with those with the CT and TT genotypes (P = 0.005 and P = 0.006). In this study, the genotype combination of AG at CFH with CT at FZD4 (SNP rs10898563) promised an increased chance of positive treatment outcome (P = 0.004). Furthermore, the association with the known genetic susceptibility loci CFH, HTRA1, and AMRS2 were confirmed, and a risk-conferring polymorphism in one new locus, LRP5, was identified. CONCLUSIONS: Genetic predisposition may account for the variability in response to anti-VEGF treatment.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Results from studies evaluating the ARMS2 A69S and HTRA1 promoter polymorphisms are also conflicting with regard to treatment response and no definitive conclusions can be drawn.9–11”
From Pharmacogenetics for Genes Associated with Age-related Macular Degeneration in the Comparison of AMD Treatments Trials (CATT) (2013) · cites this paper as [11]
Citations
Cites
Ranibizumab for Neovascular Age-Related Macular Degeneration
Rosenfeld, P. J., Brown, D. M., Heier, J. S., Boyer, D. S., Kaiser, P. K., Chung, C. Y., & Kim, R. Y. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054481 · Cited by 5,886
Bootstrap Methods and Their Application
Loughin, T. M., Davison, A. C., & Hinkley, D. V. (1999) · Journal of the American Statistical Association · doi:10.2307/2669707 · Cited by 5,418
Models for Longitudinal Data: A Generalized Estimating Equation Approach
Zeger, S. L., Liang, K.-Y., & Albert, P. S. (1988) · Biometrics · doi:10.2307/2531734 · Cited by 4,505 · cited 1×
“Resampling was performed separately in patients with one or with two treated eyes and iterated 5000 times.(50,51)”
MethodComplement factor H polymorphism in age-related macular degeneration
Klein, R. J., Zeiss, C., Chew, E. Y., Tsai, J.-Y., Sackler, R. S., Haynes, C., Henning, A. K., SanGiovanni, J. P., Mane, S. M., Mayne, S. T., et al. (2005) · Science · doi:10.1126/science.1109557 · Cited by 4,492
Ranibizumab versus Verteporfin for Neovascular Age-Related Macular Degeneration
Brown, D. M., Kaiser, P. K., Michels, M., Soubrane, G., Heier, J. S., Kim, R. Y., Sy, J. P., & Schneider, S. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa062655 · Cited by 3,522
Interaction revisited: the difference between two estimates.
Altman, D. G., & Bland, J. M. (2003) · BMJ · doi:10.1136/bmj.326.7382.219 · Cited by 3,203
VEGF receptor signalling ? in control of vascular function
Olsson, A.-K., Dimberg, A., Kreuger, J., & Claesson-Welsh, L. (2006) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1911 · Cited by 3,122 · cited 1×
“One of the most important seems to be the production of vascular endothelial growth factor (VEGF).(1,2) Intravitreal injection of the anti-vascular endothelial growth factor (anti-VEGF) compounds, ranibizumab (Lucentis; Novartis, Basel, Switzerland; and Genentech Inc.”
BackgroundComplement factor H polymorphism and age-related macular degeneration
Edwards, A. O., Ritter, R., Abel, K. J., Manning, A., Panhuysen, C., & Farrer, L. A. (2005) · Science · doi:10.1126/science.1110189 · Cited by 2,449
Complement factor H variant increases the risk of age-related macular degeneration
Haines, J. L., Hauser, M. A., Schmidt, S., Scott, W. K., Olson, L. M., Gallins, P., Spencer, K. L., Kwan, S. Y., Noureddine, M., Gilbert, J. R., et al. (2005) · Science · doi:10.1126/science.1110359 · Cited by 2,424
(1999) · Archives of Ophthalmology · doi:10.1001/archopht.117.10.1329 · Cited by 2,192
New Visual Acuity Charts for Clinical Research
Ferris, F. L., Kassoff, A., Bresnick, G. H., & Bailey, I. (1982) · American Journal of Ophthalmology · doi:10.1016/0002-9394(82)90197-0 · Cited by 2,142
Hageman, G. S., Anderson, D. H., Johnson, L. V., Hancox, L. S., Taiber, A. J., Hardisty, L. I., Hageman, J. L., Stockman, H. A., Borchardt, J. D., Gehrs, K. M., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0501536102 · Cited by 1,961
The AMD Genetics Clinical Study Group, Gold, B., Merriam, J. E., Zernant, J., Hancox, L. S., Taiber, A. J., Gehrs, K., Cramer, K., Neel, J., Bergeron, J., et al. (2006) · Nature Genetics · doi:10.1038/ng1750 · Cited by 1,075 · cited 1×
“Among them are components of the complement system,(11,12) such as complement factor H (CFH) and component factors C3, C2, and B.(16,17) Other physiological responses, such as stress responses, may also play a role in AMD.”
BackgroundSignal transduction by VEGF receptors in regulation of angiogenesis and lymphangiogenesis
Shibuya, M., & Claesson-Welsh, L. (2006) · Experimental Cell Research · doi:10.1016/j.yexcr.2005.11.012 · Cited by 1,062 · cited 1×
“It is encoded by the gene kinase insert domain receptor (KDR).(57) The intronic sequence variant that we tested in KDR lies within one of the haplotype blocks that were recently reported to lack association with AMD in a Caucasian population.”
BackgroundHTRA1 Promoter Polymorphism in Wet Age-Related Macular Degeneration
DeWan, A., Liu, M., Hartman, S., Zhang, S. S.-M., Liu, D. T. L., Zhao, C., Tam, P. O. S., Chan, W. M., Lam, D. S. C., Snyder, M., et al. (2006) · Science · doi:10.1126/science.1133807 · Cited by 876
A Variant of the HTRA1 Gene Increases Susceptibility to Age-Related Macular Degeneration
Yang, Z., Camp, N. J., Sun, H., Tong, Z., Gibbs, D., Cameron, D. J., Chen, H., Zhao, Y., Pearson, E., Li, X., et al. (2006) · Science · doi:10.1126/science.1133811 · Cited by 796
Rivera, A., Fisher, S. A., Fritsche, L. G., Keilhauer, C. N., Lichtner, P., Meitinger, T., & Weber, B. H. F. (2005) · Human Molecular Genetics · doi:10.1093/hmg/ddi353 · Cited by 788
Bone mineral density, osteoporosis, and osteoporotic fractures: a genome-wide association study
Richards, J., Rivadeneira, F., Inouye, M., Pastinen, T., Soranzo, N., Wilson, S., Andrew, T., Falchi, M., Gwilliam, R., Ahmadi, K., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60599-1 · Cited by 682 · cited 1×
“The SNP in LRP5 has been used in other association studies.(48)”
MethodBressler, N. M. (2002) · American Journal of Ophthalmology · doi:10.1016/s0002-9394(01)01237-5 · Cited by 666
Maller, J., George, S., Purcell, S., Fagerness, J., Altshuler, D., Daly, M. J., & Seddon, J. M. (2006) · Nature Genetics · doi:10.1038/ng1873 · Cited by 599 · cited 2×
“The combination of various genetic factors could modify the effect on AMD exerted by single loci as first shown by Maller et al.(43) and later repeated by others.”
BackgroundYe, X., Wang, Y., Cahill, H., Yu, M., Badea, T. C., Smallwood, P. M., Peachey, N. S., & Nathans, J. (2009) · Cell · doi:10.1016/j.cell.2009.07.047 · Cited by 469 · cited 2×
“We also examined a possible effect of VEGF receptor 2, encoded by the gene KDR, as well as that of two factors playing an important role in the process of vascularization: the low density lipoprotein receptor–related protein 5 (LRP5) and the frizzled homolog 4 (FZD4).(52) The minor allele (T) and its genotype of SNP r…”
BackgroundResultNeale, B. M., Fagerness, J., Reynolds, R., Sobrin, L., Parker, M., Raychaudhuri, S., Tan, P. L., Oh, E. C., Merriam, J. E., Souied, E., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0912019107 · Cited by 442 · cited 1×
“A similar situation has recently been reported, where association of LIPC and HDL with AMD is thought likely to be due to another factor, acting within a common pathway of lipid metabolism.(60) The general validity of our results has to be confirmed in additional patient cohorts.”
ResultKanda, A., Chen, W., Othman, M., Branham, K. E. H., Brooks, M., Khanna, R., He, S., Lyons, R., Abecasis, G. R., & Swaroop, A. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0703933104 · Cited by 441
Age-related macular degeneration is associated with an unstable ARMS2 (LOC387715) mRNA
Fritsche, L. G., Loenhardt, T., Janssen, A., Fisher, S. A., Rivera, A., Keilhauer, C. N., & Weber, B. H. F. (2008) · Nature Genetics · doi:10.1038/ng.170 · Cited by 400 · cited 8×
“The protein is encoded by HTRA1,18,19 and DNA sequence variants at this locus have been shown to associate with AMD.”
BackgroundInfluentialSwaroop, A., Chew, E. Y., Bowes Rickman, C., & Abecasis, G. R. (2009) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev.genom.9.081307.164350 · Cited by 270 · cited 1×
“Genetic factors that influence the development of AMD have been primarily identified through association studies with DNA sequence variants.(9) Several of the identified proteins respond to systemic and local inflammation.”
BackgroundY402H polymorphism of complement factor H affects binding affinity to C-reactive protein
Laine, M., Jarva, H., Seitsonen, S., Haapasalo, K., Lehtinen, M. J., Lindeman, N., Anderson, D. H., Johnson, P. T., Järvelä, I., Jokiranta, T. S., et al. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.6.3831 · Cited by 246
Thakkinstian, A., Han, P., McEvoy, M., Smith, W., Hoh, J., Magnusson, K., Zhang, K., & Attia, J. (2006) · Human Molecular Genetics · doi:10.1093/hmg/ddl220 · Cited by 223
Bressler, S. B. (2009) · Ophthalmology · doi:10.1016/j.ophtha.2009.06.045 · Cited by 205
Brantley, M. A., Fang, A. M., King, J. M., Tewari, A., Kymes, S. M., & Shiels, A. (2007) · Ophthalmology · doi:10.1016/j.ophtha.2007.09.008 · Cited by 201 · cited 2×
“Of interest, treatment with the other anti-VEGF compound, bevacizumab, showed a similar association with improved VA.7 Strong support for the involvement of FZD4 comes from our observation that individuals who were simultaneously heterozygous for the SNPs in both loci, CFH and FZD4, seem to fare better after ranibizum…”
BackgroundInfluentialSpencer, K. L., Hauser, M. A., Olson, L. M., Schmidt, S., Scott, W. K., Gallins, P., Agarwal, A., Postel, E. A., Pericak-Vance, M. A., & Haines, J. L. (2007) · Human Molecular Genetics · doi:10.1093/hmg/ddm146 · Cited by 190
Haines, J. L., Schnetz-Boutaud, N., Schmidt, S., Scott, W. K., Agarwal, A., Postel, E. A., Olson, L., Kenealy, S. J., Hauser, M., Gilbert, J. R., et al. (2006) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.05-0116 · Cited by 189
VEGF polymorphisms are associated with neovascular age-related macular degeneration
Churchill, A. J. (2006) · Human Molecular Genetics · doi:10.1093/hmg/ddl238 · Cited by 189 · cited 1×
“VEGF-A was suggested to be a risk factor for neovascular AMD on the basis of the association of SNPs in the promoter and intron of the gene.(22) Hence, we find it possible that the treatment outcome could also be influenced by VEGFA.”
BackgroundComplement, Age-Related Macular Degeneration and a Vision of the Future
Gehrs, K. M., Jackson, J. R., Brown, E. N., Allikmets, R. L., & Hageman, G. S. (2010) · Archives of Ophthalmology · doi:10.1001/archophthalmol.2010.18 · Cited by 174 · cited 1×
“Complement factor H plays an important role in the innate immune system, specifically in the regulation of induction of the alternative pathway.(11) The C-variant (p.”
BackgroundGrisanti, S., & Tatar, O. (2008) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2008.05.002 · Cited by 165 · cited 1×
“One of the most important seems to be the production of vascular endothelial growth factor (VEGF).(1,2) Intravitreal injection of the anti-vascular endothelial growth factor (anti-VEGF) compounds, ranibizumab (Lucentis; Novartis, Basel, Switzerland; and Genentech Inc.”
BackgroundLee, A. Y., Raya, A. K., Kymes, S. M., Shiels, A., & Brantley, M. A. (2009) · British Journal of Ophthalmology · doi:10.1136/bjo.2008.150995 · Cited by 134 · cited 1×
“CFH Y402H variant.(8) In our study, however, the injection frequency was similar for GRs and PRs.”
BackgroundThe molecular genetic basis of age-related macular degeneration: an overview
Katta, S., Kaur, I., & Chakrabarti, S. (2009) · Journal of Genetics · doi:10.1007/s12041-009-0064-4 · Cited by 121
Moisseiev, J. (1995) · Archives of Ophthalmology · doi:10.1001/archopht.1995.01100020069031 · Cited by 114
Genetic factors of age-related macular degeneration
Tuo, J., Bojanowski, C. M., & Chan, C. (2004) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2004.02.001 · Cited by 109 · cited 1×
“Several of the identified proteins respond to systemic and local inflammation.(10) Among them are components of the complement system,(11,12) such as complement factor H (CFH) and component factors C3, C2, and B.”
BackgroundA model for familial exudative vitreoretinopathy caused by LPR5 mutations
Xia, C.-H., Liu, H., Cheung, D., Wang, M., Cheng, C., Du, X., Chang, B., Beutler, B., & Gong, X. (2008) · Human Molecular Genetics · doi:10.1093/hmg/ddn047 · Cited by 109 · cited 1×
“Lrp5 / knockout mice show a lack of development of a complete vasculature in the deeper plexus of the retina and Müller cell–specific glutamine transporter Slc38a5 expression is significantly reduced.(59) These observations make LRP5 a promising candidate to affect AMD.”
BackgroundDesign of Case‐controls Studies with Unscreened Controls
Moskvina, V., Holmans, P., Schmidt, K. M., & Craddock, N. J. (2005) · Annals of Human Genetics · doi:10.1111/j.1529-8817.2005.00175.x · Cited by 101 · cited 1×
“DNA of individuals representing the general population was used as the control for SNP analysis.(26) These individuals were not age matched and did not undergo clinical assessment for the present study.”
MethodC2 and CFB Genes in Age-Related Maculopathy and Joint Action with CFH and LOC387715 Genes
Jakobsdottir, J., Conley, Y. P., Weeks, D. E., Ferrell, R. E., & Gorin, M. B. (2008) · PLoS ONE · doi:10.1371/journal.pone.0002199 · Cited by 97
Vascular Endothelial Growth Factor Gene Polymorphisms in Age-related Macular Degeneration
Lin, J.-M., Wan, L., Tsai, Y., Lin, H., Tsai, Y., Lee, C.-C., Tsai, C., Tseng, S.-H., & Tsai, F. (2008) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2008.01.027 · Cited by 96
Xu, Y.-L., Guan, N., Xu, J., Yang, X., Ma, K., Zhou, H., Zhang, F., Snellingen, T., Jiao, Y., Liu, X., et al. (2008) · PubMed Central · Cited by 88
Ormsby, R. J., Ranganathan, S., Tong, J. C., Griggs, K. M., Dimasi, D. P., Hewitt, A. W., Burdon, K. P., Craig, J. E., Hoh, J., & Gordon, D. L. (2008) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.07-1297 · Cited by 87
Francis, P. J., Zhang, H., DeWan, A. T., Hoh, J. J., & Klein, M. L. (2008) · PubMed Central · Cited by 73
Kaur, I., Katta, S., Hussain, A., Hussain, N., Mathai, A., Narayanan, R., Hussain, A., Reddy, R. K., Majji, A. B., Das, T., et al. (2008) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.07-0560 · Cited by 72
Boekhoorn, S. S., Isaacs, A. J., Uitterlinden, A. G., van Duijn, C. M., Hofman, A., de Jong, P. T. V. M., & Vingerling, J. R. (2008) · Ophthalmology · doi:10.1016/j.ophtha.2008.06.026 · Cited by 63 · cited 1×
“Especially in the context of anti-VEGF treatment it is noteworthy that DNA sequence variants in the VEGFA gene were found to be associated with AMD,(22,23) although these results have not been confirmed in all patient populations.(24,25) The purpose of the study was to search for genetic factors that associate with tr…”
BackgroundPolymorphisms in the VEGFA and VEGFR-2 genes and neovascular age-related macular degeneration.
Fang, A., Lee, A., Kulkarni, M., Osborn, M. P., & Brantley, M. A. (2009) · PubMed · Cited by 61
Weger, M., Renner, W., Steinbrugger, I., Köfer, K., Wedrich, A., Groselj‐Strele, A., El‐Shabrawi, Y., Schmut, O., & Haas, A. (2007) · PubMed · Cited by 59
Feng, X., Xiao, J., Longville, B., Tan, A. X. J., Wu, X. N., Cooper, M. N., McAllister, I. L., Isaacs, T., Palmer, L. J., & Constable, I. J. (2009) · Ophthalmology · doi:10.1016/j.ophtha.2009.03.011 · Cited by 54
Kaur, I., Katta, S., Reddy, R. K., Narayanan, R., Mathai, A., Majji, A. B., & Chakrabarti, S. (2010) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.09-4135 · Cited by 51 · cited 1×
“Among them are components of the complement system,(11,12) such as complement factor H (CFH) and component factors C3, C2, and B.(16,17) Other physiological responses, such as stress responses, may also play a role in AMD.”
BackgroundComplement Factor H Polymorphism in Age-Related Macular Degeneration
Narayanan, R., Butani, V., Boyer, D. S., Atilano, S. R., Resende, G. P., Kim, D. S., Chakrabarti, S., Kuppermann, B. D., Khatibi, N. H., Chwa, M., et al. (2007) · Ophthalmology · doi:10.1016/j.ophtha.2006.10.035 · Cited by 50
Richardson, A. J., Islam, A. F. M., Guymer, R. H., Cain, M. S., & Baird, P. N. (2007) · PubMed · Cited by 47
Leveziel, N., Zerbib, J., Richard, F., Querques, G., Morineau, G., Frémeaux‐Bacchi, V., COSCAS, G. J., Soubrane, G., Benlian, P., & Souied, E. H. (2008) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.07-1540 · Cited by 47
Alterations of the 5′Untranslated Region of SLC16A12 Lead to Age-Related Cataract
Zuercher, J., Neidhardt, J., Magyar, I., Labs, S., Moore, A. T., Tanner, F. C., Waseem, N. H., Schorderet, D. F., Munier, F. L., Bhattacharya, S. S., et al. (2010) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.10-5193 · Cited by 44 · cited 1×
“Venous blood was collected in EDTA tubes, and genomic DNA was extracted as described.(34) DNA concentration was adjusted to 10 ng/ L.”
MethodSelf-citationResponse to Ranibizumab Therapy in Neovascular AMD – An Evaluation of Good and Bad Responders
Menghini, M., Kurz-Levin, M. M., Amstutz, C. A., Michels, S., Windisch, R., Barthelmes, D., & Sutter, F. (2010) · Klinische Monatsblätter für Augenheilkunde · doi:10.1055/s-0029-1245203 · Cited by 26 · cited 1×
“Several years of clinical application of anti-VEGF drugs have shown a broad range of responses, with a substantial fraction of patients experiencing further deterioration of VA despite intensive and regular treatment.(5) Few studies have been undertaken to investigate the relationship between genetic factors and photo…”
BackgroundSelf-citation
Cited by
Pennington, K. L., & DeAngelis, M. M. (2016) · Eye and Vision · doi:10.1186/s40662-016-0063-5 · Cited by 480
Risk factors and biomarkers of age-related macular degeneration
Lambert, N. G., ElShelmani, H., Singh, M. K., Mansergh, F. C., Wride, M. A., Padilla, M., Keegan, D., Hogg, R. E., & Ambati, B. K. (2016) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2016.04.003 · Cited by 351
“Patients with the CC Y402H genotype for CFH show significantly less improvements in visual acuity after anti-VEGF treatment than compared to CFH genotypes of TC and TT (Brantley et al., 2007; Kloeckener-Gruissem et al., 2011; Nischler et al., 2011; Teper et al., 2010).”
Clinical pharmacology of intravitreal anti-VEGF drugs
Fogli, S., Del Re, M., Rofi, E., Posarelli, C., Figus, M., & Danesi, R. (2018) · Eye · doi:10.1038/s41433-018-0021-7 · Cited by 224
Predictors of anti-VEGF treatment response in neovascular age-related macular degeneration
Finger, R. P., Wickremasinghe, S. S., Baird, P. N., & Guymer, R. H. (2014) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2013.03.009 · Cited by 144
Hagstrom, S. A., Ying, G.-S., Pauer, G. J. T., Sturgill-Short, G. M., Huang, J., Callanan, D. G., Kim, I. K., Klein, M. L., Maguire, M. G., & Martin, D. F. (2013) · Ophthalmology · doi:10.1016/j.ophtha.2012.11.037 · Cited by 142
Metadata
- Authors
- Kloeckener-Gruissem, B., Barthelmes, D., Labs, S., Schindler, C., Kurz-Levin, M., Michels, S., Fleischhauer, J., Berger, W., Sutter, F., & Menghini, M.
- Affiliations
- From the Institute of Medical Molecular Genetics, University of Zurich, Schwerzenbach, Switzerland; the 2Department of Biology, ETHZ (Eidgenössische Technische Hochschule Zürich), Zurich, Switzerland;
- The University of Sydney (AU)
- University of Zurich (CH)
- Swiss Tropical and Public Health Institute (CH)
- University Hospital Zurich (CH)
- Triemli Hospital (CH)
- Corresponding author
- Barthelmes, Daniel
- Labs, Stephan
- Schindler, Christian
- Kurz-Levin, Malaika
- Michels, Stephan
- Fleischhauer, Johannes
- Berger, Wolfgang
- Sutter, Florian
- Menghini, Moreno
- Venue
- Investigative Opthalmology & Visual Science
- Published
- 2011-06-30
- Volume
- 52
- Issue
- 7
- Pages
- 4694
- ISSN
- 0146-0404 (ISSN-L)
- 1552-5783
- OpenAlex
- W2018291910
- Cited by
- 120
- References
- 57
- Citations by year
- 2026: 3 · 2025: 1 · 2024: 2 · 2022: 5 · 2021: 4 · 2020: 3 · 2019: 7 · 2018: 9 · 2017: 8 · 2016: 7 · 2015: 14 · 2014: 16 · 2013: 21 · 2012: 18
- FWCI
- 17.10
- Type
- journal article
- Language
- en
- Open access
- green
- doi.org
- Locations
- Investigative Ophthalmology & Visual Science (publishedVersion, public-domain)
- PubMed (publishedVersion)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion)
- Zurich Open Repository and Archive (University of Zurich)
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Health Sciences › Medicine › Ophthalmology › Ocular Diseases and Behçet’s Syndrome
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Retinal Imaging and Analysis
- Keywords
- neovascular age-related macular degeneration, ranibizumab, anti-VEGF therapy, treatment response variability, genetic susceptibility, complement factor H, CFH Y402H polymorphism, FZD4, LRP5, HTRA1, VEGF-A, KDR, visual acuity, genetic association
- MeSH terms
- Ranibizumab, High-Temperature Requirement A Serine Peptidase 1, Aged, Aged, 80 and over, Antibodies, Monoclonal, DNA, Dose-Response Relationship, Drug, Female, Fluorescein Angiography, Follow-Up Studies, Fundus Oculi, Genotype, Humans, Macular Degeneration, Male, Polymorphism, Genetic, Complement Factor B, Proteins, Serine Endopeptidases, Time Factors, Visual Acuity, Retinal Neovascularization, Polymerase Chain Reaction, Complement Factor H, Genetic Predisposition to Disease, Tomography, Optical Coherence, Vascular Endothelial Growth Factor A, Intravitreal Injections, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.